A Phase 1 interventional study of TV-46046 - 400 mg/mL and TV-46046 - 200 mg/mL in Pregnancy and Contraception, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Completed at 2 sites in United States. Open to female participants aged 18 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-02-12.
Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this pharmacodynamic and pharmacokinetic study is to identify a dose of TV-46046 (within the range 80 to 300 mg) that is both safe and consistent with contraceptive effect when injected every 6 months.
Teva Branded Pharmaceutical Products R&D, Inc. is the lead sponsor of 206 studies on the registry; none are open to participants now.
Of its 49 completed or terminated interventional studies of FDA-regulated products, 47 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
has had a normal mammogram within the last year (for Part 1 only)
Exclusion Criteria:
has hypertension:
has systemic lupus erythematosus
used any of the following medications within 1 month prior to enrollment:
in the opinion of the investigator, potentially at elevated risk of infection (eg, HIV -positive partner, IV drug use by self or by partner)
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: TV-46046 - 400 mg/mL
Drug: TV-46046 - 200 mg/mL
Drug page: Medroxyprogesterone Acetate
A single subcutaneous injection in the abdomen of undiluted TV-46046 - 400 mg/mL
Drug page: Medroxyprogesterone Acetate
A single subcutaneous injection in the abdomen of saline-diluted TV-46046 - 200 mg/mL
Part 1: Serum Medroxyprogesterone Acetate (MPA) Concentration at Day 1
'Overall number of participants analyzed' = participants evaluable for this outcome measure.
Time frame: Day 1
Part 1: Serum MPA Concentration at Day 7
Time frame: Day 7
Part 1: Serum MPA Concentration at Day 28
Time frame: Day 28
Part 1: Serum MPA Concentration at Day 91
Time frame: Day 91
Part 1: Serum MPA Concentration at Day 182
Time frame: Day 182
Part 1: Serum MPA Concentration at Day 210
Time frame: Day 210
Part 1: Maximum Observed Serum Concentration (Cmax) of MPA
Time frame: Day 0 up to Week 52
Part 1: Observed Serum Drug Concentration at Day 182 (C182) of MPA
Time frame: Day 182
Part 1: Time to Reach Cmax (Tmax) of MPA
Time frame: Day 0 up to Week 52
Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Day 182 (AUC0-182) of MPA
Time frame: Day 0 up to Day 182
Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Day 210 (AUC0-210) of MPA
Time frame: Day 0 up to Day 210
Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Infinity (AUC0-∞) of MPA
Time frame: Day 0 up to Week 52
Part 1: Apparent Terminal Half-life (t1/2) of MPA
Time frame: Day 0 up to Week 52
Part 2: Time to Ovulation
Ovulation was defined as a single elevated serum progesterone ≥4.7 ng/mL.
Time frame: Day 0 up to Week 78
Part 1: Time to Ovulation
Ovulation was defined as a single elevated serum progesterone ≥4.7 ng/mL. Time to ovulation was computed as the difference in days between detection of the first post-randomization elevated progesterone and the date of treatment initiation. Median time to ovulation was derived using Kaplan-Meier estimate.
Time frame: Day 0 up to Week 78
Part 2: Cmax of MPA
Time frame: Day 0 up to Week 52
Part 2: Tmax of MPA
Time frame: Day 0 up to Week 52
Part 2: Observed Serum Drug Concentration at Day 210 (C210) of MPA
Time frame: Day 0 up to Day 210
Part 2: C182 of MPA
Time frame: Day 0 up to Day 182
Part 2: AUC0-182 of MPA
Time frame: Day 0 up to Day 182
Part 2: AUC0-210 of MPA
Time frame: Day 0 up to Day 210
Part 2: AUC0-∞ of MPA
Time frame: Day 0 up to Week 52
Part 2: Apparent Terminal Half Life (t1/2) of MPA
Time frame: Day 0 up to Week 52
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
Time frame: Day 0 up to Week 78
This was a 2-part study: Part 1 (Exploratory Pharmacokinetics \[PK\]) and Part 2 (Dose-range Finding).
| Milestone | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Started | 6 | 6 |
| Received at least 1 dose of study drug | 6 | 6 |
| Completed | 4 | 5 |
| Not completed | 2 | 1 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Discontinued early due to personal decision | 1 | 1 |
'Overall number of participants analyzed' = participants evaluable for this outcome measure.
| nanograms (ng)/milliliter (mL) | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Serum Medroxyprogesterone Acetate (MPA) Concentration at Day 1 | 0.36 ± 0.13 | 0.67 ± 0.22 |
| ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Serum MPA Concentration at Day 7 | 0.37 ± 0.10 | 0.70 ± 0.22 |
| ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Serum MPA Concentration at Day 28 | 0.36 ± 0.07 | 0.69 ± 0.25 |
| ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Serum MPA Concentration at Day 91 | 0.41 ± 0.13 | 0.62 ± 0.09 |
| ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Serum MPA Concentration at Day 182 | 0.22 ± 0.08 | 0.17 ± 0.10 |
| ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Serum MPA Concentration at Day 210 | 0.20 ± 0.05 | 0.12 ± 0.09 |
| ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Maximum Observed Serum Concentration (Cmax) of MPA | 0.53 (0.43 to 0.64) | 0.97 (0.73 to 1.29) |
| ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Observed Serum Drug Concentration at Day 182 (C182) of MPA | 0.21 (0.14 to 0.31) | 0.14 (0.05 to 0.40) |
| days | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Time to Reach Cmax (Tmax) of MPA | 9.49 (1.96 to 40.96) | 47.99 (7.10 to 84.01) |
| days*ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Day 182 (AUC0-182) of MPA | 58.61 (44.75 to 76.76) | 97.72 (82.20 to 116.18) |
| days*ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Day 210 (AUC0-210) of MPA | 63.91 (48.78 to 83.74) | 103.11 (88.40 to 120.27) |
| days*ng/mL | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Area Under the Serum Drug Concentration by Time Curve From Time 0 to Infinity (AUC0-∞) of MPA | 94.56 (81.16 to 110.16) | 114.13 (98.77 to 131.88) |
| days | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Apparent Terminal Half-life (t1/2) of MPA | 82.87 (32.12 to 213.80) | 42.34 (23.20 to 77.28) |
Ovulation was defined as a single elevated serum progesterone ≥4.7 ng/mL.
No measurements were reported for this outcome.
Ovulation was defined as a single elevated serum progesterone ≥4.7 ng/mL. Time to ovulation was computed as the difference in days between detection of the first post-randomization elevated progesterone and the date of treatment initiation. Median time to ovulation was derived using Kaplan-Meier estimate.
| days | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Part 1: Time to Ovulation | 328 (279 to 434) | 251 (196 to 291) |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
An adverse event (AE) was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious adverse events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. AEs were considered TEAEs if onset occurred on or after the first dose date. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.
| Participants | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | 6 | 6 |
Collected over Day 0 up to Week 78. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 (TV-46046 - Undiluted) | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Group 2 (TV-46046 - Saline-diluted) | 0/6 (0%) | 1/6 (16.7%) | 6/6 (100%) |
| Event | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Suicide attemptPsychiatric disorders | 0/6 | 1/6 |
| Event | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) |
|---|---|---|
| Injection site reactionGeneral disorders | 5/6 | 4/6 |
| Bacterial vaginosisInfections and infestations | 2/6 | 0/6 |
| Viral upper respiratory tract infectionInfections and infestations | 2/6 | 2/6 |
| RashSkin and subcutaneous tissue disorders | 0/6 | 2/6 |
| Abdominal painGastrointestinal disorders | 0/6 | 1/6 |
| Chest painGeneral disorders | 1/6 | 0/6 |
| PyrexiaGeneral disorders | 1/6 | 0/6 |
| ThirstGeneral disorders | 0/6 | 1/6 |
| HypersensitivityImmune system disorders | 1/6 | 0/6 |
| UrticariaImmune system disorders | 0/6 | 1/6 |
Treated population included all screened participants who were enrolled and received a dose of study drug.
| Age, Continuous(years) | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) | Total |
|---|---|---|---|
| Mean | 29.5 ± 4.04 | 34.2 ± 5.08 | 31.8 ± 5.01 |
| Sex: Female, Male(Participants) | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) | Total |
|---|---|---|---|
| Female | 6 | 6 | 12 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) | Total |
|---|---|---|---|
| Hispanic or Latino | 2 | 0 | 2 |
| Not Hispanic or Latino | 4 | 6 | 10 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1 (TV-46046 - Undiluted) | Group 2 (TV-46046 - Saline-diluted) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 5 | 5 |
| White | 5 | 1 | 6 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2016 to primary completion in Dec 2018, 25 months.
Results were first posted in Feb 2024, 5 years 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Medroxyprogesterone Acetate
Teva Branded Pharmaceutical Products R&D, Inc. →